Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1551-1561

  Ma, Qi ^a   Zhang, Kun ^a   Yao, Hang Ping ^b   Zhou, Yong Qing ^b   Padhye, Snehal ^a   Wang, Ming Hai ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antagonistic activity; Epithelial cancer; Receptor tyrosine kinase; Signal transduction; Truncated variant

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MACROPHAGE ACTIVATING FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN RON RECEPTOR TYROSINE KINASE; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; RON DELTA 85; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BETA CHAIN; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENIC ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; EXON; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; SIGNAL TRANSDUCTION; STOP CODON;

AMINO ACID SEQUENCE; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOPRECIPITATION; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NEOPLASMS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77951548324     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000642     Document Type: Article

References (38)

1. Wagh PK, Peace BE and Waltz SE: Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33, 2008. (Pubitemid 351942429)
2. Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12: 273-281, 2005. (Pubitemid 40616491)
3. Wang MH, Lee W, Luo YL, Weis MT and Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 213: 402-411, 2007. (Pubitemid 350206512)
4. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH and Bishio JM: The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 104: 7570-7575, 2007. (Pubitemid 47185947)
5. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH and Waltz SE: Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 66: 11967-11974, 2006. (Pubitemid 46094210)
6. Chen YQ, Zhou YQ, Fu LH, Wang D and Wang MH: Multiple pulmonary adenomas in the lung of transgenic mice over-expressing the RON receptor tyrosine kinase. Recepteur d' origine nantais. Carcinogenesis 23: 1811-1819, 2002.
7. Wang MH, Yao HP and Zhou YQ: Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 27: 641-650, 2006.
8. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL and Pereira DS: Therapeutic implications of a human neutralizing antibody to the macrophagestimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66: 9162-9170, 2006. (Pubitemid 44521136)
9. Xu XM, Wang D, Shen Q, Chen YQ and Wang MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23: 8464-8474, 2004. (Pubitemid 39540797)
10. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL and Dussault I: Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 68: 6680-6687, 2008.
11. Dussault I and Bellon SF: From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 9: 221-229, 2009.
12. Wang MH, Julian FM, Breathnach R, Godowski PJ, Takehara T, Yoshikawa W, Hagiya M and Leonard EJ: Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain. J Biol Chem 272: 16999-167004, 1997. (Pubitemid 27289804)
13. Danilkovitch A, Miller M and Leonard EJ: Interaction of macrophage-stimulating protein with its receptor. Residues critical for beta chain binding and evidence for independent alpha chain binding. J Biol Chem 274: 29937-29943, 1999. (Pubitemid 29483373)
14. Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-1202, 1993. (Pubitemid 23129841)
15. Stamos J, Lazarus RA, Yao X, Kirchhofer D and Wiesmann C: Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 23: 2325-2335, 2004. (Pubitemid 38954840)
16. Basilico C, Arnesano A, Galluzzo M, Comoglio PM and Michieli P: A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 283: 21267-21277, 2008.
17. Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ and Lerman MI: The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem 279: 3726-3732, 2006. (Pubitemid 38140616)
18. Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164, 2007. (Pubitemid 47538834)
19. Zhang K, Yao HP and Wang MH: Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility. Carcinogenesis 29: 552-559, 2008. (Pubitemid 351404871)
20. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W and Wang MH: Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5: 1179-1186, 2006. (Pubitemid 44772234)
21. Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: Generation of different splicing variants and their oncogenic potential. Oncogene 22: 186-197, 2003. (Pubitemid 36174176)
22. Wang MH, Lao WF, Wang D, Luo YL and Yao HP: Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ther 6: 1121-1129, 2007. (Pubitemid 351574966)
23. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ and Lerman MI: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 29: 147-156, 2000.
24. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P and Comoglio PM: Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19: 3041-3049, 2000.
25. Peace BE, Hill KJ, Degen SJ and Waltz SE: Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp Cell Res 289: 317-325, 2003. (Pubitemid 37117417)
26. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM and Mendel DB: A selective small molecule inhibitor of c-Met kinase inhibits c- Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 7345-7355, 2003. (Pubitemid 37413476)
27. Wortinger M and Liu L: RON splice variant prevalence in human tumors. Proc 99th AACR Annual meeting. Abst. 3610, 2008.
28. Eckerich C, Schulte A, Martens T, Zapf S, Westphal M and Lamszus K: RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem 109: 969-980, 2009.
29. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L and Comoglio PM: Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 61-73, 2004. (Pubitemid 38903162)
30. Liu Z, Neiss N, Zhou S, Henne-Bruns D, Korc M, Bachem M and Kornmann M: Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res 67: 2712-2719, 2007. (Pubitemid 46548959)
31. Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I and Ayalon- Soffer M: A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Clin Cancer Res 14: 4612-4621, 2008.
32. Kong-Beltran M, Stamos J and Wickramasinghe D: The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6: 75-84, 2004. (Pubitemid 38903163)
33. Boccaccio C and Comoglio PM: Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637-645, 2006. (Pubitemid 44140861)
34. Xiao ZQ, Chen YQ and Wang MH: Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. Biochem Biophys Res Commun 267: 669-675, 2000.
35. Xu XM, Zhou YQ and Wang MH: Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem 280: 25087-25094, 2005.
36. Thangasamy A, Rogge J and Ammanamanchi S: Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells. J Biol Chem 284: 14001-14010, 2009.
37. Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW and Brattain MG: Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 284: 10912-10922, 2009.
38. Wang MH, Skeel A, Yoshimura T, Copeland TD, Sakaguchi K and Leonard EJ: Antibodies to macrophage stimulating protein (MSP): specificity, epitope interactions, and immunoassay of MSP in human serum. J Leukoc Biol 54: 289-295, 1993. (Pubitemid 23317695)